{"result": {"id": "3cfd81cf-d4a8-4de8-9358-ff886a69f27a", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>MAIW<|>PERSON<|>MaiW is a researcher who contributed to the study on white-coat hypertension as a risk factor for cardiovascular diseases and total mortality>  \n##  \n(\"entity\"<|>FRANKLIN SS<|>PERSON<|>Franklin SS is a researcher who studied the cardiovascular risk of white-coat hypertension and its implications in diabetes mellitus>  \n##  \n(\"entity\"<|>THIJS L<|>PERSON<|>Thijs L is a researcher involved in studies on white-coat hypertension, masked hypertension, and risk stratification by ambulatory blood pressure monitoring>  \n##  \n(\"entity\"<|>ASAYAMA K<|>PERSON<|>Asayama K is a researcher who contributed to studies on white-coat hypertension and its cardiovascular risks>  \n##  \n(\"entity\"<|>MANCIA G<|>PERSON<|>Mancia G is a researcher who studied the effect of long-term antihypertensive treatment on white-coat hypertension>  \n##  \n(\"entity\"<|>FAGARD RH<|>PERSON<|>Fagard RH is a researcher involved in the Systolic Hypertension in Europe (Syst-Eur) trial>  \n##  \n(\"entity\"<|>BULPITT CJ<|>PERSON<|>Bulpitt CJ is a researcher who studied white-coat hypertension in the very elderly trial>  \n##  \n(\"entity\"<|>HUANG QF<|>PERSON<|>Huang QF is a researcher who contributed to studies on ambulatory blood pressure monitoring for diagnosing and managing hypertension>  \n##  \n(\"entity\"<|>WANG GL<|>PERSON<|>Wang GL is a researcher who studied anthropometric and lifestyle factors associated with white-coat, masked, and sustained hypertension>  \n##  \n(\"entity\"<|>BRGULJAN-HITIJ J<|>PERSON<|>Brguljan-Hitij J is a researcher involved in risk stratification by ambulatory blood pressure monitoring>  \n##  \n(\"entity\"<|>WEI FF<|>PERSON<|>Wei FF is a researcher who studied the persistence of masked hypertension in Chinese patients>  \n##  \n(\"entity\"<|>ZHANG DY<|>PERSON<|>Zhang DY is a researcher who contributed to studies on masked hypertension subtypes and target organ damage>  \n##  \n(\"entity\"<|>JULIUS S<|>PERSON<|>Julius S is a researcher who studied the feasibility of treating prehypertension with an angiotensin-receptor blocker>  \n##  \n(\"entity\"<|>LÜDERS S<|>PERSON<|>Lüders S is a researcher involved in the PHARAO study on preventing hypertension with ramipril>  \n##  \n(\"entity\"<|>EL-ATAT F<|>PERSON<|>El-Atat F is a researcher who studied the pathophysiology and management of diabetes, hypertension, and cardiovascular derangements>  \n##  \n(\"entity\"<|>SCHRIER RW<|>PERSON<|>Schrier RW is a researcher who studied the effects of aggressive blood pressure control in normotensive type 2 diabetic patients>  \n##  \n(\"entity\"<|>HUANG JF<|>PERSON<|>Huang JF is a researcher involved in the ANTI-MASK trial on antihypertensive treatment in masked hypertension>  \n##  \n(\"entity\"<|>KARIO K<|>PERSON<|>Kario K is a researcher who contributed to the HOPE Asia network consensus statement on morning hypertension management>  \n##  \n(\"entity\"<|>SYSTOLIC HYPERTENSION IN EUROPE (SYST-EUR) TRIAL<|>EVENT<|>A clinical trial investigating the response to antihypertensive therapy in older patients with sustained and nonsustained systolic hypertension>  \n##  \n(\"entity\"<|>HYPERTENSION IN THE VERY ELDERLY TRIAL<|>EVENT<|>A trial studying whether white-coat hypertension requires treatment in patients over age 80>  \n##  \n(\"entity\"<|>PHARAO STUDY<|>EVENT<|>A prevention trial investigating the use of ramipril in patients with high-normal blood pressure>  \n##  \n(\"entity\"<|>ANTI-MASK TRIAL<|>EVENT<|>A randomized, double-blind, placebo-controlled trial on antihypertensive treatment in masked hypertension for target organ protection>  \n##  \n(\"entity\"<|>HOPE ASIA NETWORK<|>ORGANIZATION<|>A network that provides consensus statements on hypertension management, including morning hypertension>  \n##  \n(\"relationship\"<|>FRANKLIN SS<|>THIJS L<|>Franklin SS and Thijs L collaborated on research about white-coat hypertension and its cardiovascular risks<|>7>  \n##  \n(\"relationship\"<|>ASAYAMA K<|>FRANKLIN SS<|>Asayama K and Franklin SS co-authored studies on white-coat hypertension<|>6>  \n##  \n(\"relationship\"<|>MANCIA G<|>FAGARD RH<|>Mancia G and Fagard RH are researchers in the field of hypertension studies<|>5>  \n##  \n(\"relationship\"<|>BULPITT CJ<|>HYPERTENSION IN THE VERY ELDERLY TRIAL<|>Bulpitt CJ was involved in the Hypertension in the Very Elderly Trial<|>8>  \n##  \n(\"relationship\"<|>LÜDERS S<|>PHARAO STUDY<|>Lüders S was a key researcher in the PHARAO study<|>9>  \n##  \n(\"relationship\"<|>HUANG JF<|>ANTI-MASK TRIAL<|>Huang JF was involved in the ANTI-MASK trial<|>9>  \n##  \n(\"relationship\"<|>KARIO K<|>HOPE ASIA NETWORK<|>Kario K contributed to the HOPE Asia Network's consensus statement<|>8>  \n##  \n(\"relationship\"<|>SYSTOLIC HYPERTENSION IN EUROPE (SYST-EUR) TRIAL<|>FAGARD RH<|>Fagard RH was part of the Syst-Eur trial investigators<|>8>  \n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558960, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 1385, "prompt_tokens": 2954, "total_tokens": 4339, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 1162}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: MaiW , etal. White-coathypertension is arisk factorforcardiovasculardiseasesand totalmortality[J]. J Hypertens,2017,35(4) :677-688.\n[413]  Franklin SS, Thijs L, Asayama K, et al.  The cardiovascular risk ofwhite-coathypertension[J]. JAm CollCardiol, 2016, 68\n(19) :2033-2043.\n[414]  AsayamaK, LiY, FranklinSS, etal. Cardiovascularrisk asso- ciated with white-coat hypertension: con side of the argument [J]. Hypertension,2017,70(4) :676-682.\n\n\n[415]  ManciaG, FacchettiR, ParatiG, etal. Effectoflong-term an- tihypertensivetreatmenton white-coathypertension[J]. Hyper- tension,2014,64(6) :1388-1398.\n[416]  Fagard RH, Staessen JA, ThijsL, et al.  Response to antihy- pertensivetherapy in older patients with sustained and nonsus- tained systolic hypertension.   Systolic Hypertension in Europe (Syst-Eur) trial investigators[J]. Circulation, 2000, 102(10) :  1139-1144.\n[417]  BulpittCJ, BeckettN, PetersR, etal. Doeswhite coathyper- tension requiretreatmentoverage80? Resultsofthe hyperten- sion in theveryelderlytrialambulatorybloodpressuresidepro- ject[J]. Hypertension,2013,61(1) :89-94.\n[418]  Huang QF, Yang WY, Asayama K, et al.  Ambulatory blood pressuremonitoring to diagnose and manage hypertension[J].   Hypertension,2021,77(2) :254-264.\n[419]  WangGL, LiY, StaessenJA, etal. Anthropometricand lifes- tyle factors associated with white-coat,  masked and sustained hypertension in a Chinese population[J]. J Hypertens, 2007, 25\n(12) :2398-2405.\n[420]  FranklinSS, ThijsL, LiY, etal. Masked hypertension india- betesmellitus: treatment implications for clinicalpractice[J].   Hypertension,2013,61(5) :964-971.\n[421]  Brguljan-HitijJ, ThijsL, LiY, etal. Risk stratificationbyam- bulatoryblood pressure monitoring across JNC classes of con- ventionalblood pressure[J]. Am JHypertens,2014,27(7) : 956- 965.\n[422]  WeiFF, LiY, ZhangL, etal. Persistenceofmaskedhyperten- sion in Chinesepatients[J]. Am J Hypertens, 2016, 29(3) : 326- 331.\n[423]  ZhangDY, ChengYB, GuoQH, etal. Subtypesofmaskedhy- pertension and targetorgandamageinuntreatedoutpatients[J].   BloodPress,2020,29(5) :299-307.\n[424]  ZhangDY, GuoQH, AnDW , etal. A comparativemeta-analy- sisofprospective observational studies on masked hypertension and masked uncontrolled hypertension defined by ambulatory and homeblood pressure[J]. J Hypertens, 2019, 37(9) : 1775- 1785.\n[425]  Julius S, NesbittSD, Egan BM, et al.  Feasibility of treating prehypertension with an angiotensin-receptorblocker[J]. N Engl JMed,2006,354(16) :1685-1697.\n[426]  LüdersS, SchraderJ, BergerJ, et al.  The PHARAO study:  prevention of hypertension with the angiotensin-converting en- zymeinhibitorramiprilinpatientswithhigh-normalblood pres- sure: a prospective, randomized, controlled prevention trial of theGerman HypertensionLeague[J]. J Hypertens,2008,26(7) :  1487-1496.\n[427]  El-AtatF, McFarlane SI, SowersJR.  Diabetes, hypertension,  and cardiovascularderangements: pathophysiology and manage- ment[J]. CurrHypertensRep,2004,6(3) :215-223.\n[428]  SchrierRW , EstacioRO, EslerA, etal.  Effects ofaggressive blood pressure control in normotensive type2 diabetic patients onalbuminuria, retinopathyandstrokes[J]. KidneyInt,2002,61\n(3) :1086-1097.\n[429]  Huang JF, LiMX, Zhang DY, et al.  Antihypertensive treat- mentinmaskedhypertensionfortargetorganprotection(ANTI-\n\n\n\nMASK) :  a randomized,  double-blind,  placebo-controlled trial [J]. eClinialMedicine,2024,74:102736.\n[430]  KarioK, WangJG, Chia YC, etal. The HOPE Asia network\n　2022 up-date consensus statement on morning hypertension management[J\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_34e3436724ab05b5d61c7415ce7d8aef5a0f9b2ec9b25e7331a5a61bc4163368_v2"}